Tirzepatide beats semaglutide on average weight loss in the head-to-head evidence available today and it also carries the higher price and a broader side effect profile at the top doses. The honest comparison is not a winner announcement. It is a set of tradeoffs covering how much loss each delivers, at what cost, at what dose, with what side effects and how each decision changes if you are paying cash without insurance. This guide works through each of those tradeoffs with the actual trial numbers and the actual 2026 prices, so you can choose with your clinician rather than from an ad.

Key takeaways
  • In the head-to-head SURMOUNT-5 trial, tirzepatide delivered 20.4% average weight loss at 72 weeks versus 13.7% for semaglutide.
  • SURMOUNT-1 showed tirzepatide up to about 22.5% and STEP-1 showed semaglutide about 14.9% over similar windows.
  • In 2026, Zepbound self-pay commonly reports $299 to $449 a month by dose through LillyDirect and Wegovy self-pay commonly reports $499 a month.
  • Tirzepatide and semaglutide are different molecules and the choice between them is a clinical decision made on your labs, history and tolerance.
  • Our fee is a flat $299 a month for the doctor and the quarterly Biomarker Audit. Medication is a separate charge billed by the pharmacy at its own price with zero markup.

What the head-to-head evidence shows

The single most useful data point for this comparison is the trial that actually put the two molecules in the same room. In SURMOUNT-5, published in the New England Journal of Medicine in 2025, adults with obesity or overweight received tirzepatide or semaglutide for 72 weeks under otherwise identical trial conditions. The tirzepatide group lost an average of 20.4% of body weight. The semaglutide group lost an average of 13.7%. The relative advantage was 47%, which is the largest head-to-head margin between any two branded weight loss medications studied to date.

The individual trials fill in the picture around that number. In SURMOUNT-1, the pivotal tirzepatide trial, participants at the highest dose lost an average of about 22.5% of body weight over 72 weeks. In STEP-1, the pivotal semaglutide trial, participants lost an average of about 14.9% over 68 weeks. Those two trials were not designed as head-to-head comparisons and reading their numbers against each other has limits. The head-to-head design of SURMOUNT-5 exists precisely to remove those limits, which is why it is the number to anchor on.

Weight loss in the pivotal trials

TrialDrugDurationAverage weight loss
SURMOUNT-1, highest doseTirzepatide 15 mg72 weeks~22.5%
SURMOUNT-5, head to headTirzepatide 15 mg72 weeks20.4%
SURMOUNT-5, head to headSemaglutide 2.4 mg72 weeks13.7%
STEP-1Semaglutide 2.4 mg68 weeks~14.9%

What the trials do not tell you is what any of this means for your body. Individual results vary and the averages conceal a wide spread in both directions. A patient who loses 9% on tirzepatide and a patient who loses 17% on semaglutide both exist in real clinics and neither result invalidates the trial averages. The averages tell your clinician where to start. The labs tell both of you whether it is working.

Doses, titration and the practical differences

The two medications work differently and are dosed differently and those differences matter for the day-to-day experience.

Tirzepatide is a dual agonist acting on both GIP and GLP-1 receptors. Semaglutide acts on the GLP-1 receptor alone. Tirzepatide is dosed in 2.5, 5, 7.5, 10, 12.5 and 15 milligram steps. Semaglutide for weight loss is dosed at 0.25, 0.5, 1.0, 1.7 and 2.4 milligrams. Both titrate upward over weeks toward the dose that produces the result with tolerable side effects and both carry the same class of gastrointestinal side effects at titration, nausea being the most common, with tirzepatide showing somewhat higher rates at the top doses in the trials.

One clinical distinction matters more than the averages. Tirzepatide carries an approved indication for obstructive sleep apnea in adults with obesity, which is a legitimate deciding factor for patients whose sleep study is part of their story. Semaglutide carries an approved indication for cardiovascular risk reduction in adults with overweight or obesity and established cardiovascular disease, which matters for patients whose story is cardiac rather than metabolic. The headline weight loss numbers do not capture those differences and neither does the price list.

What each costs in 2026, stated plainly

Prices change and the sources below were checked for 2026. Hedge accordingly.

Eli Lilly publishes self-pay vial pricing through LillyDirect. Zepbound self-pay commonly reports between $299 and $449 a month depending on dose, with lower doses at the lower end of the range. Novo Nordisk publishes self-pay pricing through NovoCare and Wegovy self-pay commonly reports $499 a month. These are the pharmacy's prices and they can move. We set none of them and add nothing to them.

The price difference between the two molecules is real and the cheaper molecule is not automatically the better value. Value depends on the result delivered per dollar, which depends on how your body responds. A patient doing well on semaglutide at $499 is buying a better outcome than a patient losing nothing on tirzepatide at $299. This is why the medication decision is a clinical decision rather than a price comparison and why the quarterly Biomarker Audit matters, because it tells you whether the molecule you chose is actually delivering on your body rather than on a chart.

GoodLife Health. Medicine that builds on itself, $299 a month: 90-day labs, your clinician, branded GLP-1s, one platform. See if you qualify.GoodLife Health. $299 a month. Everything talks to everything: quarterly labs read by your clinician, branded GLP-1s prescribed from them, every result and dose tracked on one platform. See if you qualify.

How to choose between them

We will not pretend there is a single right answer, because there is not. The choice depends on your body, your history and your goals and it should be made with a clinician looking at your labs rather than at a leaderboard. That said, the factors are concrete enough to name.

If maximum average weight loss matters most to you and you tolerate titration well, tirzepatide is the molecule the head-to-head evidence favors. If you have established cardiovascular disease, semaglutide's cardiovascular indication is a real deciding factor. If you have obstructive sleep apnea, tirzepatide's approval there is a real one. If cost is the binding constraint, Zepbound's lower self-pay doses make it the cheaper entry point in 2026 and the difference is large enough to matter over a year.

What should not drive the choice is anything on our side, because nothing on our side earns a dollar from it. The fee is a flat $299 a month for the clinical relationship and four Biomarker Audits a year, with a two month commitment at the start paid as a single $598 charge covering the first two months together. From month three it is month to month and you can cancel anytime after that commitment. Medication is a separate charge billed by the pharmacy at its own price with zero markup, no molecule upcharge and no dose escalation fee. We make money when you get healthier, not when your dose gets stronger and we earn nothing extra whichever molecule you and your clinician choose.

The question worth asking before you choose

What does each molecule do for my body, read against my labs, at what cost per month and with what side effects? Any program that answers before looking at your labs is selling rather than treating.

The objections a cash-pay patient raises, answered

Patients comparing these two molecules with their own money on the table ask harder questions than trial readouts answer and each deserves a direct answer.

"Tirzepatide wins on the averages, so why would I choose semaglutide?" Because averages are not prescriptions. If your history includes cardiovascular disease, semaglutide's approved indication there is a benefit the weight loss averages do not capture. If you tolerated semaglutide well in the past and failed to adhere to tirzepatide's titration, the molecule you will actually stay on is the better molecule for you, because adherence beats pharmacology every time it is tested.

"Why is Zepbound cheaper than Wegovy if it works better?" Because the manufacturers set their self-pay prices strategically rather than clinically and price on the self-pay market reflects commercial positioning as much as efficacy. Zepbound's lower-tier doses are priced to win the cash-pay market and the strategy has worked. None of that changes the clinical comparison, which the trials settled and none of it should substitute for the clinician's read of your labs and history.

"Can I start on the cheaper dose and climb only if I need to?" Yes and that is exactly how honest titration works on either molecule, start low, assess response and side effects at each step and escalate only when the response justifies it. Where the programs differ is in who profits when the dose climbs and that question has a structural answer rather than a marketing one.

"What if I plateau at the top dose?" Then the regimen conversation is about everything except the dose, protein, resistance work, sleep, adherence and the quarterly audit is what tells the clinician which lever to pull. Escalation has nowhere to go past the top dose, so the plateau plan that depends on escalation has no plan.

Where the Biomarker Audit fits in

Whichever molecule you start, the evidence that it is working is in the labs rather than the scale alone. The quarterly Biomarker Audit reads HbA1c and insulin markers, the lipid panel with ApoB, hs-CRP and the full hormone and thyroid panels, as one system. On a GLP-1, that is the difference between knowing your weight changed and knowing what else changed with it, which is the question a dose-based business has no reason to ask and you have every reason to.

Clinical care is delivered by physicians of Beluga Health, P.A., an independent Florida professional corporation licensed in all 50 states, working under GoodLife Health's clinical protocols. All labs run through the Beluga Health lab network and additional labs beyond the quarterly cadence are billed to you at pass-through cost.

FAQ

Is tirzepatide more effective than semaglutide for weight loss? On average, yes. The head-to-head evidence is direct. In SURMOUNT-5, tirzepatide produced 20.4% average weight loss at 72 weeks versus 13.7% for semaglutide. Individual results vary and a clinician should read both options against your labs rather than the averages.

How much does tirzepatide cost compared with semaglutide? In 2026, Zepbound self-pay commonly reports $299 to $449 a month through LillyDirect depending on dose and Wegovy self-pay commonly reports $499 a month through NovoCare. Your pharmacy bills that price directly and we add nothing to it.

Can I switch from semaglutide to tirzepatide or the other way? Yes, under a clinician's supervision, usually with a titration period on the new molecule rather than starting at the equivalent dose. The two work differently and switching is a clinical decision made on labs and response rather than a swap.

Which has fewer side effects? Both carry the same class of gastrointestinal side effects at titration, nausea being the most common. Tirzepatide shows somewhat higher rates at the top doses in the trials. The main lever on side effects is titrating to the lowest dose that holds the result.

Do I need labs before starting either one? Yes. A comprehensive panel before prescribing is the difference between treatment and a vending machine. Our quarterly Biomarker Audit covers the metabolic, lipid, inflammation, hormone and thyroid picture and it repeats every 90 days.

Does the GoodLife Health fee change if I switch molecules? No. The fee is a flat $299 a month for the doctor and the quarterly Biomarker Audit, with a two month commitment at the start paid as a single $598 charge. Medication is billed by the pharmacy at its own price with zero markup, so switching molecules changes their bill and never ours.

Related Guides

References

  1. SURMOUNT-5: Tirzepatide versus Semaglutide Once Weekly in Obesity, NEJM 2025. NEJM
  2. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1), NEJM 2022. PubMed 35658024
  3. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP-1), NEJM 2021. PubMed 33567185
  4. LillyDirect Zepbound self-pay pricing, Eli Lilly 2026. lilly.com
  5. NovoCare self-pay pharmacy, Novo Nordisk 2026. novocare.com